Awakn Life Sciences reposted this
Solvonis Therapeutics plc strengthens board with addition of Dr Renata Crome @SolvonisTx #LSE #SVNS http://ow.ly/B4Kg106282c
Awakn Life Sciences
Biotechnology Research
Therapeutics for substance use and mental health disorders
About us
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders. Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting approximately 29 million adults in the US and approximately 40 million in the US and key European markets for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
- Website
-
http://www.awaknlifesciences.com
External link for Awakn Life Sciences
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Toronto
- Type
- Public Company
- Founded
- 2020
- Specialties
- Biotechnology, Clinical Stage, Alcohol Use Disorder, and Addiction
Locations
-
Primary
Get directions
Toronto, CA
Employees at Awakn Life Sciences
Updates
-
Awakn Life Sciences reposted this
With only one week until #PharmaSynergyRx on February 27-28, our team is excited to share that new companies keep joining the event! :) - 3,500 meeting requests have already been exchanged among BD&L professionals focused on prescription medicines. - Regional & Global companies from over 50 countries are engaging in B2B partnering meetings. - 250+ High-profile #BD & #Licensing and #Csuite executives ensure these discussions will lead to meaningful partnerships. - Every company is carefully selected from a global pool of Rx-focused pharma and biopharma, ensuring a perfectly compatible audience and unstoppable partnering activity. #PharmaSynergy is committed to adding value to these excellent opportunities. We understand your time is valuable, and we aim to create meaningful discussions about new products, untapped geographies, fresh insights, and innovative business models. We are pleased to announce that Anthony Tennyson, CEO of Solvonis Therapeutics plc who will join the speaker lineup on February 27 with a Spotlight Presentation: Solvonis Therapeutics – Advancing Treatments for Mental Health and Addiction.
-
-
Awakn Life Sciences reposted this
Our CEO, Anthony Tennyson, presenting Solvonis Therapeutics plc #PharmaSynergyRx next week in London. See here for more info, https://lnkd.in/ezRmB6sx
With only one week until #PharmaSynergyRx on February 27-28, our team is excited to share that new companies keep joining the event! :) - 3,500 meeting requests have already been exchanged among BD&L professionals focused on prescription medicines. - Regional & Global companies from over 50 countries are engaging in B2B partnering meetings. - 250+ High-profile #BD & #Licensing and #Csuite executives ensure these discussions will lead to meaningful partnerships. - Every company is carefully selected from a global pool of Rx-focused pharma and biopharma, ensuring a perfectly compatible audience and unstoppable partnering activity. #PharmaSynergy is committed to adding value to these excellent opportunities. We understand your time is valuable, and we aim to create meaningful discussions about new products, untapped geographies, fresh insights, and innovative business models. We are pleased to announce that Anthony Tennyson, CEO of Solvonis Therapeutics plc who will join the speaker lineup on February 27 with a Spotlight Presentation: Solvonis Therapeutics – Advancing Treatments for Mental Health and Addiction.
-
-
Awakn is advancing three programs targeting #mentalhealth and #addiction: AWKN-001 (combination therapy for severe #AUD), AWKN-002 (esketamine oral thin film for moderate-to-severe AUD), and AWKN-SND-14 (pre-clinical investigation for #PTSD). Find details from Solvonis Therapeutics plc: https://bit.ly/40PhrsB
-
In a recent interview with Proactive Investor's Stephen Gunnion, Solvonis Therapeutics plc CEO, Anthony Tennyson explained Awakn's exciting developments regarding AWKN-002, a drug candidate targeting moderate to severe #AlcoholUseDisorder (#AUD). Watch here: https://bit.ly/3PMvWr2
Solvonis Therapeutics says FDA supports Phase 2b for AWKN-002 candidate
proactiveinvestors.co.uk
-
Awakn Life Sciences reposted this
Solvonis Therapeutics plc Therapeutics chairman on the future of biotech & neuroscience M&A #LSE #SVNS http://ow.ly/kzwG105YgZP
-
-
Solvonis Therapeutics plc has recently issued an update on the research and development progress of Awakn, the company that Solvonis plans to acquire. For more information, please visit: https://bit.ly/40PhrsB
-
Awakn Life Sciences reposted this
Solvonis Therapeutics plc (LSE:SVNS) has updated investors on the research and development (R&D) advancements at Awakn Life Sciences Corp, the biotechnology it intends to acquire. Awakn is advancing three programmes focused on addressing mental health and addiction disorders. More at #Proactive #ProactiveInvestors http://ow.ly/YyU0105XYqF
-
Awakn is planning to submit its IND application and initiate the Phase 2b clinical trial for AWKN-002 in patients with #AUD once a scientific bridge to the reference product has been suitably established. https://bit.ly/40HHCBJ
-
Awakn Life Sciences reposted this
Looking forward to speaking at Mello Events on Monday and providing an update on our pans and progress in building Solvonis Therapeutics plc into a leading neuropsych biotech focused on mental health and addiction
Our CEO, Anthony Tennyson, will be presenting at Mello Events MelloMonday on Monday 27 January 2025. Visit https://lnkd.in/eYhku5vr and register for free using code SHME100